Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis.Dermatologica. 1987;175(4):183-90 Griffith RS, Walsh DE, Myrmel KH, Thompson RW, Behforooz A. A double-blind, placebo-controlled, multicenter trial of oral L-lysine monohydrochloride for the prevention and treatment of recurrent herpes simplex (HSV) infection was conducted. The treatment group was given L-Lysine monohydrochloride tablets (1,000 mg L-lysine per dose) 3 times a day for 6 months. A total of 27 (6 male and 21 female) subjects on L-lysine and 25 (6 male and 19 female) subjects on placebo completed the trial. The L-lysine treatment group had an average of 2.4 (p less than 0.05) less HSV infections, symptoms were significantly (p less than 0.05) diminished in severity and healing time was significantly reduced (p less than 0.05). L-Lysine appears to be an effective agent for reduction of occurrence, severity and healing time for recurrent HSV infection. |
Page Tools:
What's New:
- The collapse of the ‘European Union’ and the threat of a nuclear crisis
- The ‘assassination’ of former Polish president Lech Kaczynski: Who benefits?
- The latest attempt of the drug lobby to discredit the health benefits of vitamins
- Victory over Cancer!
- Dismantling the ‘Brussels EU’ – a precondition for global natural health freedom
- Brussels EU continues attempts to curtail spread of lifesaving natural health information
- How to use diagnostic technologies wisely and for the benefit of your health
- Radio interview – Jon Rappoport Show
- President Obama, Wake Up America!
- Wake Up, America! Prevent Dicatorship And War!
- What the 'Brussels EU' isn't telling you about the Lisbon Treaty
- The Oil Cartel's Goal: Toppling the Obama Government
